133 related articles for article (PubMed ID: 38686517)
1. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
[TBL] [Abstract][Full Text] [Related]
2. Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.
Fletcher L; Burrowes S; Sabin LL; McCann N; Khan GK; Ruiz-Mercado G; Johnson S; Kimmel SD; Pierre C; Drainoni ML
AIDS Patient Care STDS; 2024 May; 38(5):221-229. PubMed ID: 38656905
[TBL] [Abstract][Full Text] [Related]
3. Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed.
Hickey MD; Grochowski J; Mayorga-Munoz F; Oskarsson J; Imbert E; Spinelli M; Szumowski JD; Appa A; Koester K; Dauria EF; McNulty M; Colasanti J; Havlir DV; Gandhi M; Christopoulos KA
J Acquir Immune Defic Syndr; 2024 Jul; 96(3):280-289. PubMed ID: 38534179
[TBL] [Abstract][Full Text] [Related]
4. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
Wohlfeiler MB; Brunet L; Cochran Q; Fusco JS; Hsu RK; Fusco GP
J Int Assoc Provid AIDS Care; 2024; 23():23259582241245223. PubMed ID: 38613372
[TBL] [Abstract][Full Text] [Related]
5. Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South.
Collins LF; Corbin-Johnson D; Asrat M; Morton ZP; Dance K; Condra A; Jenkins K; Todd-Turner M; Sumitani J; Smith BL; Armstrong WS; Colasanti JA
Open Forum Infect Dis; 2022 Sep; 9(9):ofac455. PubMed ID: 36147599
[TBL] [Abstract][Full Text] [Related]
6. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.
Erguera XA; Koester KA; Diaz Tsuzuki M; Dance KV; Flores R; Kerman J; McNulty MC; Colasanti JA; Collins LF; Montgomery ET; Johnson MO; Sauceda JA; Christopoulos KA
AIDS Behav; 2024 Jul; 28(7):2226-2238. PubMed ID: 38598026
[TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
8. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
[TBL] [Abstract][Full Text] [Related]
9. Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project.
Nguyen N; Lane B; Golub SA; Chastain C; Zucker J; King K; Terry M; Burdge J; Carnevale C; Muscarella A; Castor D; Kutner B; Meyers K
J Int AIDS Soc; 2024 Jul; 27 Suppl 1(Suppl 1):e26282. PubMed ID: 38965977
[TBL] [Abstract][Full Text] [Related]
10. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
11. Patient Attitudes Toward Self- or Partner-, Friend-, or Family-Administered Long-acting Injectable Antiretroviral Therapy: A Mixed-Methods Study Across 3 Urban Human Immunodeficiency Virus Clinics.
Collins LF; Koester KA; McNulty MC; Montgomery ET; Johnson MO; Neilands TB; Dilworth SE; Sauceda JA; Dance K; Erguera X; Diaz Tsuzuki M; Gutierrez JI; Christopoulos KA; Colasanti JA
Open Forum Infect Dis; 2024 Jun; 11(6):ofae265. PubMed ID: 38854389
[TBL] [Abstract][Full Text] [Related]
12. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
Scheibe K; Urbańska A; Serwin K; Parczewski M
Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
[TBL] [Abstract][Full Text] [Related]
13. Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
Nguyen NM; Kavanagh R; Gozar M; Cabral D; Goetz H; Cha A; McGowan JP; Pao ML
AIDS Patient Care STDS; 2024 Mar; 38(3):115-122. PubMed ID: 38471090
[TBL] [Abstract][Full Text] [Related]
14. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of cabotegravir for HIV treatment and prevention.
Canetti D; Spagnuolo V
Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
[No Abstract] [Full Text] [Related]
16. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
Czarnogorski M; Garris CP; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26003. PubMed ID: 36094142
[TBL] [Abstract][Full Text] [Related]
17. Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine.
Hill LA; Abulhosn KK; Yin JF; Bamford LP
AIDS; 2023 Mar; 37(4):605-609. PubMed ID: 36730069
[TBL] [Abstract][Full Text] [Related]
18. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
Bares SH; Scarsi KK
Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
[TBL] [Abstract][Full Text] [Related]
19. Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design.
Farooq HZ; Apea V; Kasadha B; Ullah S; Hilton-Smith G; Haley A; Scherzer J; Hand J; Paparini S; Phillips R; Orkin CM
BMJ Open; 2023 Jul; 13(7):e070666. PubMed ID: 37423623
[TBL] [Abstract][Full Text] [Related]
20. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
